da S Mororó Jânio, Meira Débora D, Bizzo Solange M D, Altoé Lorena S C, Casotti Matheus C, Santana Gabriel M, Louro Luana S, Louro Thomas E S, Vicente Creuza R, de Araújo Bruno C, Groisman Sonia, de Carvalho Elizeu F, Louro Iúri D
Departamento de Química Fundamental, Instituto de Química, Universidade de São Paulo (USP), São Paulo, Brazil.
Department of Biological Sciences, Universidade Federal Do Espírito Santo (UFES), Av. Fernando Ferrari, N. 514, Prédio Ciências Biológicas, Bloco A, Sala 106, Cep: 29.075-910, Vitória, Espírito Santo, Brazil.
Med Oncol. 2025 Aug 3;42(9):401. doi: 10.1007/s12032-025-02929-5.
Epithelial ovarian cancer (EOC) is highly angiogenic, making this tumor attractive, in the last 20 years, for analysis of clinical and biological functions of the VEGF family, relating altered expression with patient's clinical responses. Currently, analyzes and validations have yet to be made to relate vascular normalization with combinations of immune-, chemo- or radiotherapy. We review the main clinical analyses capable of identifying markers of vascular normalization including functional biomarkers (e.g., perfusion parameters by imaging techniques), molecular biomarkers (e.g., circulating protein levels and cfDNA), blood biomarkers, physiological markers and other approaches. Many markers cited here have not yet been analyzed in EOC but have shown promising results in tumors such as pancreatic and glioblastoma cancer, which share similarities with ovarian cancer. The methodologies presented have the advantage of not being invasive and immediately detecting vascular normalization, mainly using imaging techniques.
上皮性卵巢癌(EOC)具有高度血管生成性,在过去20年里,这使得该肿瘤成为分析血管内皮生长因子(VEGF)家族临床和生物学功能、将表达改变与患者临床反应相关联的热门对象。目前,尚未对血管正常化与免疫、化疗或放疗联合应用之间的关系进行分析和验证。我们综述了能够识别血管正常化标志物的主要临床分析方法,包括功能生物标志物(如通过成像技术测量的灌注参数)、分子生物标志物(如循环蛋白水平和游离DNA)、血液生物标志物、生理标志物及其他方法。这里提到的许多标志物尚未在EOC中进行分析,但在与卵巢癌有相似之处的胰腺癌和胶质母细胞瘤等肿瘤中已显示出有前景的结果。所介绍的方法具有非侵入性且能立即检测血管正常化的优点,主要是利用成像技术。
Med Oncol. 2025-8-3
Cochrane Database Syst Rev. 2022-9-26
Cochrane Database Syst Rev. 2016-6-29
Cochrane Database Syst Rev. 2011-8-10
Cochrane Database Syst Rev. 2022-8-30
Cochrane Database Syst Rev. 2013-7-9
Front Pharmacol. 2023-11-15
Eur J Nucl Med Mol Imaging. 2023-8
Gynecol Oncol. 2023-3